T1	Modifier 39 48	recurrent
E1	Modifier:T1 
T2	Or 49 51	or
E2	Or:T2 
T3	Modifier 52 69	metastasis breast
E3	Modifier:T3 
T4	Condition 70 76	cancer
E4	Condition:T4 Name:T64
T5	Condition 97 115	measurable disease
E5	Condition:T5 Name:T65
T6	Observation 135 174	Eastern Cooperative Oncology Group(ECOG
E6	Observation:T6 Name:T66
T7	Eq-Comparison 195 201	0 or 1
E7	Eq-Comparison:T7 Value:T67
T8	Condition 217 231	organ function
E8	Condition:T8 Name:T69
T9	Temporal-Connection 278 286	prior to
E9	Temporal-Connection:T9 
A1	Temporal-Connection-Type-Value E9 before
T10	Study 291 296	study
E10	Study:T10 
T11	Eq-Comparison 333 340	History
E11	Eq-Comparison:T11 Temporal-Period:T70
T12	Modifier 344 355	anti-cancer
E12	Modifier:T12 
T13	Procedure 356 363	therapy
E13	Procedure:T13 
T14	Exception 381 390	exception
E14	Exception:T14 
T15	Eq-Comparison 398 403	prior
E15	Eq-Comparison:T15 Temporal-Period:T74
T16	Procedure 404 420	hormonal regimen
E16	Procedure:T16 
T17	Condition 425 428	MBC
E17	Condition:T17 
T18	Eq-Comparison 436 443	History
E18	Eq-Comparison:T18 Temporal-Period:T75
T19	Drug 451 477	tyrosine kinase inhibitors
E19	Drug:T19 Name:T76
T20	Or 478 480	or
E20	Or:T20 
T21	Drug 481 500	monoclonal antibody
E21	Drug:T21 Name:T77
T22	Modifier 505 511	breast
E22	Modifier:T22 
T23	Condition 512 518	cancer
E23	Condition:T23 Name:T78
T24	Procedure 526 535	treatment
E24	Procedure:T24 
T25	Drug 536 562	setting，except trastuzumab
E25	Drug:T25 Name:T79
T26	Modifier 575 587	neo-adjuvant
E26	Modifier:T26 
T27	Or 588 590	or
E27	Or:T27 
T28	Procedure 591 607	adjuvant setting
E28	Procedure:T28 Name:T81
T29	Negation 649 655	unable
E29	Negation:T29 
T30	Modifier 664 672	systemic
E30	Modifier:T30 
T31	Procedure 673 685	chemotherapy
E31	Procedure:T31 Name:T82
T32	Eq-Comparison 692 699	History
E32	Eq-Comparison:T32 Temporal-Period:T83
T33	Other 703 708	other
E33	Other:T33 
T34	Condition 709 719	malignancy
E34	Condition:T34 Name:T84
T35	Eq-Comparison 720 737	within the last 5
E35	Eq-Comparison:T35 Operator:T85 Temporal-Period:T86 Value:T87
T36	Condition 755 764	carcinoma
E36	Condition:T36 Name:T88
T37	Modifier 776 803	cervix，basal cell carcinoma
E37	Modifier:T37 
T38	Or 804 806	or
E38	Or:T38 
T39	Modifier 807 820	squamous cell
E39	Modifier:T39 
T40	Condition 821 830	carcinoma
E40	Condition:T40 
T41	Modifier 838 842	skin
E41	Modifier:T41 
T42	Eq-Comparison 857 867	previously
E42	Eq-Comparison:T42 Temporal-Period:T91
T43	Procedure 868 875	treated
E43	Procedure:T43 
T44	Procedure 881 896	curative intent
E44	Procedure:T44 
T45	Condition 903 911	Pregnant
E45	Condition:T45 Name:T92
T46	Or 912 914	or
E46	Or:T46 
T47	Condition 915 924	lactating
E47	Condition:T47 Name:T93
T48	Condition 947 959	childbearing
E48	Condition:T48 Name:T95
T49	Assertion 960 969	potential
E49	Assertion:T49 
A2	Assertion-Type-Value E49 hypothetical
T50	Assertion 970 982	unwilling to
E50	Assertion:T50 
A3	Assertion-Type-Value E50 hypothetical
T51	Modifier 989 1005	highly-effective
E51	Modifier:T51 
T52	Procedure 1006 1019	contraception
E52	Procedure:T52 Name:T96
T53	Temporal-Connection 1020 1026	during
E53	Temporal-Connection:T53 
A4	Temporal-Connection-Type-Value E53 during
T54	Study 1034 1039	study
E54	Study:T54 
T55	Procedure 1040 1049	treatment
E55	Procedure:T55 
T56	And 1050 1053	and
E56	And:T56 
T57	Eq-Comparison 1058 1075	at least 7 months
E57	Eq-Comparison:T57 Operator:T97 Value:T98 Temporal-Unit:T99
T58	Temporal-Connection 1076 1081	after
E58	Temporal-Connection:T58 
A5	Temporal-Connection-Type-Value E58 after
T59	Eq-Comparison 1086 1090	last
E59	Eq-Comparison:T59 Temporal-Period:T100
T60	Study 1099 1104	study
E60	Study:T60 
T61	Procedure 1105 1114	treatment
E61	Procedure:T61 
T62	Eq-Unit 25 29	HER2
T63	Polarity 30 38	positive
A6	Polarity-Value T63 positive
T64	Condition-Name 70 76	cancer
T65	Condition-Name 97 115	measurable disease
T66	Observation-Name 135 174	Eastern Cooperative Oncology Group(ECOG
A7	Observation-Type-Value T66 clinical-score
T67	Eq-Value 195 196	0
T68	Polarity 208 216	Adequate
A8	Polarity-Value T68 normal
T69	Condition-Name 217 231	organ function
T70	Eq-Temporal-Period 333 340	History
A9	Eq-Temporal-Period-Value T70 past
T71	Procedure-Name 349 363	cancer therapy
T72	Condition-Name 368 376	MBC（with
T73	Eq-Value 394 397	one
T74	Eq-Temporal-Period 398 403	prior
A10	Eq-Temporal-Period-Value T74 past
T75	Eq-Temporal-Period 436 443	History
A11	Eq-Temporal-Period-Value T75 past
T76	Drug-Name 451 477	tyrosine kinase inhibitors
T77	Drug-Name 481 500	monoclonal antibody
T78	Condition-Name 512 518	cancer
T79	Drug-Name 536 562	setting，except trastuzumab
T80	Drug-Name 575 587	neo-adjuvant
T81	Procedure-Name 591 599	adjuvant
T82	Procedure-Name 673 685	chemotherapy
T83	Eq-Temporal-Period 692 699	History
A12	Eq-Temporal-Period-Value T83 past
T84	Condition-Name 709 719	malignancy
T85	Eq-Operator 720 726	within
A13	Eq-Operator-Value T85 LTEQ
T86	Eq-Temporal-Period 731 735	last
A14	Eq-Temporal-Period-Value T86 past
T87	Eq-Value 736 737	5
T88	Condition-Name 755 764	carcinoma
T89	Condition-Name 776 803	cervix，basal cell carcinoma
T90	Condition-Name 807 830	squamous cell carcinoma
T91	Eq-Temporal-Period 857 867	previously
A15	Eq-Temporal-Period-Value T91 past
T92	Condition-Name 903 911	Pregnant
T93	Condition-Name 915 924	lactating
T94	Life-Stage-And-Gender 938 943	women
A16	Life-Stage-And-Gender-Type T94 female
T95	Condition-Name 947 959	childbearing
T96	Procedure-Name 1006 1019	contraception
T97	Eq-Operator 1058 1066	at least
A17	Eq-Operator-Value T97 GTEQ
T98	Eq-Value 1067 1068	7
T99	Eq-Temporal-Unit 1069 1075	months
A18	Eq-Temporal-Unit-Value T99 month
T100	Eq-Temporal-Period 1086 1090	last
A19	Eq-Temporal-Period-Value T100 past
